rozanolixizumab治疗全身型肌无力的安全性和有效性(MycarinG):一项随机、双盲、安慰剂对照、适应性3期研究
MycarinG是在亚洲、欧洲和北美81个门诊中心开展的随机双盲安慰剂对照适应性3期研究,纳入200例乙酰胆碱受体或肌肉特异性酪氨酸激酶抗体阳性的全身型肌无力患者,按1:1:1随机接受rozanolixizumab 7 mg/kg、10 mg/kg或安慰剂皮下输注每周一次共6周。主要终点第43天MG-ADL评分较基线变化,两个剂量组均优于安慰剂,差异有统计学意义,两组总体耐受性良好。
要点
- rozanolixizumab 7 mg/kg和10 mg/kg组第43天MG-ADL评分较基线下降均大于安慰剂组。
- 最常见治疗中出现的不良事件为头痛、腹泻和发热。
- 两个剂量组严重治疗中出现的不良事件发生率与安慰剂组相近,无死亡发生。
核心结论
- rozanolixizumab 7 mg/kg和10 mg/kg剂量在全身型肌无力患者中显示出有临床意义的患者报告和研究者评估结局改善。
- 两个剂量总体耐受性良好。
- 这些发现支持新生儿Fc受体抑制在全身型肌无力中的作用机制。
- rozanolixizumab是全身型肌无力患者一种潜在的其他治疗选择。
研究设计与样本
- MycarinG是在亚洲、欧洲和北美81个门诊中心和医院开展的随机、双盲、安慰剂对照、适应性3期研究。
- 纳入年龄≥18岁、乙酰胆碱受体或肌肉特异性酪氨酸激酶自身抗体阳性、美国肌无力基金会分级II-IVa级、MG-ADL评分至少3分(非眼部症状)且定量肌无力评分至少11分的全身型肌无力患者。
- 2019年6月3日至2021年6月30日评估300例患者资格,其中200例入组;66例(33%)随机分配至rozanolixizumab 7 mg/kg组,67例(34%)至rozanolixizumab 10 mg/kg组,67例(34%)至安慰剂组。
- 患者按1:1:1随机接受rozanolixizumab 7 mg/kg、rozanolixizumab 10 mg/kg或安慰剂皮下输注,每周一次共6周;随机化按乙酰胆碱受体和肌肉特异性酪氨酸激酶自身抗体状态分层。
- 主要疗效终点为意向治疗人群中MG-ADL评分从基线至第43天的变化;治疗中出现的不良事件在所有接受至少一剂研究药物的随机分配患者中评估。
主要发现
- MG-ADL评分从基线至第43天的最小二乘均值变化:rozanolixizumab 7 mg/kg组-3.37(标准误0.49),rozanolixizumab 10 mg/kg组-3.40(标准误0.49),安慰剂组-0.78(标准误0.49)。
- rozanolixizumab 7 mg/kg组与安慰剂组最小二乘均值差异为-2.59(95% CI -4.09至-1.25),p<0.0001;rozanolixizumab 10 mg/kg组与安慰剂组差异为-2.62(95% CI -3.99至-1.16),p<0.0001。
- 治疗中出现的不良事件:rozanolixizumab 7 mg/kg组64例中52例(81%),rozanolixizumab 10 mg/kg组69例中57例(83%),安慰剂组67例中45例(67%)。
- 最常见的治疗中出现的不良事件为头痛(rozanolixizumab 7 mg/kg组29例[45%],10 mg/kg组26例[38%],安慰剂组13例[19%])、腹泻(16例[25%]、11例[16%]、9例[13%])和发热(8例[13%]、14例[20%]、1例[1%])。
- 严重治疗中出现的不良事件:rozanolixizumab 7 mg/kg组5例(8%),10 mg/kg组7例(10%),安慰剂组6例(9%);无死亡发生。
临床怎么用
- 作者认为,rozanolixizumab是全身型肌无力患者一种潜在的其他治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Generalised myasthenia gravis is a chronic, unpredictable, and debilitating autoimmune disease. New treatments for this disease are needed because conventional therapies have limitations, such as side-effects (eg, increased infection risk) or inadequate control of symptoms. Rozanolixizumab is a neonatal Fc receptor blocker that might provide a novel therapeutic option for myasthenia gravis. We aimed to assess the safety and efficacy of rozanolixizumab for generalised myasthenia gravis. METHODS: MycarinG is a randomised, double-blind, placebo-controlled, adaptive phase 3 study done at 81 outpatient centres and hospitals in Asia, Europe, and North America. We enrolled patients (aged ≥18 years) with acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) autoantibody-positive generalised myasthenia gravis (Myasthenia Gravis Foundation of America class II-IVa), a Myasthenia Gravis Activities of Daily Living (MG-ADL) score of at least 3 (non-ocular symptoms), and a quantitative myasthenia gravis score of at least 11. Patients were randomly assigned (1:1:1) to receive subcutaneous infusions once a week for 6 weeks of either rozanolixizumab 7 mg/kg, rozanolixizumab 10 mg/kg, or placebo. Randomisation was stratified by AChR and MuSK autoantibody status. Investigators, patients, and people assessing outcomes were masked to random assignments. The primary efficacy endpoint was change from baseline to day 43 in MG-ADL score, assessed in the intention-to-treat population. Treatment-emergent adverse events (TEAEs) were assessed in all randomly assigned patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov (NCT03971422) and EudraCT (2019-000968-18); an open-label extension study has been completed (NCT04124965; EudraCT 2019-000969-21) and another is underway (NCT04650854; EudraCT 2020-003230-20). FINDINGS: Between June 3, 2019, and June 30, 2021, 300 patients were assessed for eligibility, of whom 200 were enrolled. 66 (33%) were randomly assigned to rozanolixizumab 7 mg/kg, 67 (34%) to rozanolixizumab 10 mg/kg, and 67 (34%) to placebo. Reductions in MG-ADL score from baseline to day 43 were greater in the rozanolixizumab 7 mg/kg group (least-squares mean change -3·37 [SE 0·49]) and in the rozanolixizumab 10 mg/kg group (-3·40 [0·49]) than with placebo (-0·78 [0·49]; for 7 mg/kg, least-squares mean difference -2·59 [95% CI -4·09 to -1·25], p<0·0001; for 10 mg/kg, -2·62 [-3·99 to -1·16], p<0·0001). TEAEs were experienced by 52 (81%) of 64 patients treated with rozanolixizumab 7 mg/kg, 57 (83%) of 69 treated with rozanolixizumab 10 mg/kg, and 45 (67%) of 67 treated with placebo. The most frequent TEAEs were headache (29 [45%] patients in the rozanolixizumab 7 mg/kg group, 26 [38%] in the rozanolixizumab 10 mg/kg group, and 13 [19%] in the placebo group), diarrhoea (16 [25%], 11 [16%], and nine [13%]), and pyrexia (eight [13%], 14 [20%], and one [1%]). Five (8%) patients in the rozanolixizumab 7 mg/kg group, seven (10%) in the rozanolixizumab 10 mg/kg group, and six (9%) in the placebo group had a serious TEAE. No deaths occurred. INTERPRETATION: Rozanolixizumab showed clinically meaningful improvements in patient-reported and investigator-assessed outcomes in patients with generalised myasthenia gravis, for both 7 mg/kg and 10 mg/kg doses. Both doses were generally well tolerated. These findings support the mechanism of action of neonatal Fc receptor inhibition in generalised myasthenia gravis. Rozanolixizumab represents a potential additional treatment option for patients with generalised myasthenia gravis. FUNDING: UCB Pharma.
引用
- Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023. PMID: 37059507. doi:10.1016/S1474-4422(23)00077-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。